Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Parkinson's Disease

  Free Subscription


30.03.2020

1 Biol Psychiatry
1 Int J Neurosci
2 J Neural Transm (Vienna)
6 J Neurochem
2 Mov Disord
2 Nat Rev Neurol
3 Neurobiol Dis
1 Neurol Genet
1 Neurology
1 Neuron
1 Neuropsychology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Biol Psychiatry

  1. SMELAND OB, Shadrin A, Bahrami S, Broce I, et al
    Genome-wide Association Analysis of Parkinson's Disease and Schizophrenia Reveals Shared Genetic Architecture and Identifies Novel Risk Loci.
    Biol Psychiatry. 2020 Feb 8. pii: S0006-3223(20)30061.
    PubMed         Abstract available


    Int J Neurosci

  2. MOON S, Kahya M, Lyons KE, Pahwa R, et al
    Cognitive Workload during Verbal Abstract Reasoning in Parkinson's Disease: A Pilot Study.
    Int J Neurosci. 2020 Mar 21:1-10. doi: 10.1080/00207454.2020.1746309.
    PubMed         Abstract available


    J Neural Transm (Vienna)

  3. ANTONINI A, Abbruzzese G, Berardelli A, Modugno N, et al
    The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients.
    J Neural Transm (Vienna). 2020 Mar 24. pii: 10.1007/s00702-020-02175.
    PubMed         Abstract available

  4. SKRABAL D, Tykalova T, Klempir J, Ruzicka E, et al
    Dysarthria enhancement mechanism under external clear speech instruction in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.
    J Neural Transm (Vienna). 2020 Mar 19. pii: 10.1007/s00702-020-02171.
    PubMed         Abstract available


    J Neurochem

  5. VAIKATH NN, Hmila I, Gupta V, Erskine D, et al
    Antibodies against alpha-synuclein: tools and therapies.
    J Neurochem. 2019;150:612-625.
    PubMed         Abstract available

  6. STEFANIS L, Emmanouilidou E, Pantazopoulou M, Kirik D, et al
    How is alpha-synuclein cleared from the cell?
    J Neurochem. 2019;150:577-590.
    PubMed         Abstract available

  7. GONZALEZ N, Arcos-Lopez T, Konig A, Quintanar L, et al
    Effects of alpha-synuclein post-translational modifications on metal binding.
    J Neurochem. 2019;150:507-521.
    PubMed         Abstract available

  8. KILLINGER BA, Kordower JH
    Spreading of alpha-synuclein - relevant or epiphenomenon?
    J Neurochem. 2019;150:605-611.
    PubMed         Abstract available

  9. WASSOUF Z, Schulze-Hentrich JM
    Alpha-synuclein at the nexus of genes and environment: the impact of environmental enrichment and stress on brain health and disease.
    J Neurochem. 2019;150:591-604.
    PubMed         Abstract available

  10. OUTEIRO TF, Mestre TA
    Synuclein Meeting 2019: where we are and where we need to go.
    J Neurochem. 2019;150:462-466.
    PubMed         Abstract available


    Mov Disord

  11. FEARON C, Farrell MA
    Disease-Specific Strains of alpha-Synuclein in Multiple System Atrophy and Parkinson's Disease: But Why?
    Mov Disord. 2020 Mar 23. doi: 10.1002/mds.28035.
    PubMed        

  12. SVENNINGSSON P, Odin P, Dizdar N, Johansson A, et al
    A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia.
    Mov Disord. 2020 Mar 21. doi: 10.1002/mds.28020.
    PubMed         Abstract available


    Nat Rev Neurol

  13. LEMPRIERE S
    Exosomal alpha-synuclein as a biomarker for Parkinson disease.
    Nat Rev Neurol. 2020 Mar 23. pii: 10.1038/s41582-020-0349.
    PubMed        

  14. SCHAPIRA AHV, Morris HR
    Pathogenetic insights into young-onset Parkinson disease.
    Nat Rev Neurol. 2020 Mar 24. pii: 10.1038/s41582-020-0343.
    PubMed        


    Neurobiol Dis

  15. FENYI A, Leclair-Visonneau L, Clairembault T, Coron E, et al
    Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification.
    Neurobiol Dis. 2019;129:38-43.
    PubMed         Abstract available

  16. RUSSO I, Kaganovich A, Ding J, Landeck N, et al
    Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with alpha-synuclein fibrils.
    Neurobiol Dis. 2019;129:67-78.
    PubMed         Abstract available

  17. MOREAU C, Rolland AS, Pioli E, Li Q, et al
    Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
    Neurobiol Dis. 2020 Mar 20:104846. doi: 10.1016/j.nbd.2020.104846.
    PubMed         Abstract available


    Neurol Genet

  18. CHELBAN V, Carecchio M, Rea G, Bowirrat A, et al
    MYORG-related disease is associated with central pontine calcifications and atypical parkinsonism.
    Neurol Genet. 2020;6:e399.
    PubMed         Abstract available


    Neurology

  19. WALDVOGEL D, Baumann-Vogel H, Stieglitz L, Hanggi-Schickli R, et al
    Beware of deep water after subthalamic deep brain stimulation.
    Neurology. 2020;94:39-41.
    PubMed        


    Neuron

  20. CUDDY LK, Wani WY, Morella ML, Pitcairn C, et al
    Stress-Induced Cellular Clearance Is Mediated by the SNARE Protein ykt6 and Disrupted by alpha-Synuclein.
    Neuron. 2019;104:869-884.
    PubMed         Abstract available


    Neuropsychology

  21. WILLIAMS IA, Obeso I, Jahanshahi M
    Dopaminergic medication improves cognitive control under low cognitive demand in Parkinson's disease.
    Neuropsychology. 2020 Mar 23. pii: 2020-20104-001. doi: 10.1037/neu0000629.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: